{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:49:50Z","timestamp":1792291790134,"version":"4.4.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004901","name":"FAPEMIG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["G0701500"],"award-info":[{"award-number":["G0701500"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["G1000183"],"award-info":[{"award-number":["G1000183"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["093875\/Z\/10\/Z"],"award-info":[{"award-number":["093875\/Z\/10\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.ejphar.2015.02.025","type":"journal-article","created":{"date-parts":[[2015,2,25]],"date-time":"2015-02-25T04:28:27Z","timestamp":1424838507000},"page":"112-115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Dopamine receptor partial agonists and addiction"],"prefix":"10.1016","volume":"752","author":[{"given":"Fabricio A.","family":"Moreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Dalley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2015.02.025_bib1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejphar.2014.09.004","article-title":"The antipsychotic aripiprazole selectively prevents the stimulant and rewarding effects of morphine in mice","volume":"742","author":"Almeida-Santos","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.02.025_bib2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/bcp.12116","article-title":"Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice","volume":"77","author":"Aubin","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.02.025_bib3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/bcp.12051","article-title":"Pharmacological maintenance treatments of opiate addiction","volume":"77","author":"Bell","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.02.025_bib4","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/npp.2009.162","article-title":"Dissociable control of impulsivity in rats by dopamine d2\/3 receptors in the core and shell subregions of the nucleus accumbens","volume":"35","author":"Besson","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2015.02.025_bib5","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1177\/0269881110376690","article-title":"Anti-aversive effects of the atypical antipsychotic, aripiprazole, in animal models of anxiety","volume":"25","author":"Biojone","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2015.02.025_bib6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0014-2999(95)00592-7","article-title":"Dopamine partial receptor agonists reduce ethanol intake in the rat","volume":"296","author":"Bono","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.02.025_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0920-9964(01)00185-2","article-title":"Typical antipsychotic drugs \u2013 D(2) receptor occupancy and depressive symptoms in schizophrenia","volume":"56","author":"Bressan","year":"2002","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ejphar.2015.02.025_bib8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2015.02.025_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0893-133X(88)90012-7","article-title":"The current status of the dopamine hypothesis of schizophrenia","volume":"1","author":"Carlsson","year":"1988","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2015.02.025_bib10","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1001\/jama.2014.3654","article-title":"Pharmacological treatment of Parkinson\u05f3s disease","volume":"311","author":"Connolly","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2015.02.025_bib11","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/nn1579","article-title":"Neural systems of reinforcement for drug addiction: from actions to habits to compulsion","volume":"8","author":"Everitt","year":"2005","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejphar.2015.02.025_bib12","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.biopsych.2006.04.010","article-title":"Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse","volume":"61","author":"Feltenstein","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2015.02.025_bib13","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.neubiorev.2013.08.006","article-title":"The downward spiral of chronic pain, prescription opioid misuse, and addiction: cognitive, affective, and neuropsychopharmacologic pathways","volume":"37","author":"Garland","year":"2013","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.ejphar.2015.02.025_bib14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00213-008-1079-x","article-title":"Controversies in translational research: drug self-administration","volume":"199","author":"Haney","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2015.02.025_bib15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/026988110401800308","article-title":"Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile","volume":"18","author":"Hirose","year":"2004","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2015.02.025_bib16","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.tips.2009.07.006","article-title":"Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb","volume":"30","author":"Izzo","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2015.02.025_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.alcohol.2007.11.004","article-title":"The antipsychotic aripiprazole antagonizes the ethanol- and amphetamine-induced locomotor stimulation in mice","volume":"42","author":"Jerlhag","year":"2008","journal-title":"Alcohol"},{"key":"10.1016\/j.ejphar.2015.02.025_bib18","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.tips.2004.06.005","article-title":"How antipsychotics become anti-\u201cpsychotic\u201d \u2013 from dopamine to salience to psychosis","volume":"25","author":"Kapur","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2015.02.025_bib19","doi-asserted-by":"crossref","first-page":"e1169","DOI":"10.4088\/JCP.13r08525","article-title":"Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials","volume":"74","author":"Kishi","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2015.02.025_bib20","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1098\/rstb.2008.0094","article-title":"Review. Neurobiological mechanisms for opponent motivational processes in addiction","volume":"363","author":"Koob","year":"2008","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.ejphar.2015.02.025_bib21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/npp.2009.110","article-title":"Neurocircuitry of addiction","volume":"35","author":"Koob","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2015.02.025_bib23","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ejphar.2007.09.016","article-title":"Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice","volume":"578","author":"Leite","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.02.025_bib24","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.pbb.2009.01.014","article-title":"Aripiprazole blocks reinstatement but not expression of morphine conditioned place preference in rats","volume":"92","author":"Li","year":"2009","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejphar.2015.02.025_bib25","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1017\/S1461145713001430","article-title":"Selective action of an atypical neuroleptic on the mechanisms related to the development of cocaine addiction: a pre-clinical behavioural study","volume":"17","author":"Marinho","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2015.02.025_bib26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1526-5900(03)00556-X","article-title":"Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review","volume":"4","author":"McNicol","year":"2003","journal-title":"J. Pain"},{"key":"10.1016\/j.ejphar.2015.02.025_bib27","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0301-0082(02)00009-6","article-title":"Descending control of pain","volume":"66","author":"Millan","year":"2002","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejphar.2015.02.025_bib28","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1176\/ajp.2007.164.4.630","article-title":"Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia","volume":"164","author":"Mizrahi","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2015.02.025_bib29","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejphar.2005.02.040","article-title":"Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice","volume":"512","author":"Moreira","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.02.025_bib31","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1038\/sj.npp.1300983","article-title":"Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models","volume":"31","author":"Natesan","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2015.02.025_bib32","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/nn1578","article-title":"Is there a common molecular pathway for addiction?","volume":"8","author":"Nestler","year":"2005","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejphar.2015.02.025_bib33","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1124\/pr.55.4.4","article-title":"International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology","volume":"55","author":"Neubig","year":"2003","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2015.02.025_bib34","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1098\/rstb.2008.0105","article-title":"Review. Evidence-based treatments of addiction","volume":"363","author":"O\u05f3Brien","year":"2008","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.ejphar.2015.02.025_bib35","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1177\/0269881105053308","article-title":"The place of partial agonism in psychiatry: recent developments","volume":"19","author":"Ohlsen","year":"2005","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2015.02.025_bib36","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0893-133X(01)00270-6","article-title":"Dopamine partial agonist reverses amphetamine withdrawal in rats","volume":"25","author":"Orsini","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2015.02.025_bib37","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0074-7742(08)60669-8","article-title":"Neurochemical bases of locomotion and ethanol stimulant effects","volume":"39","author":"Phillips","year":"1996","journal-title":"Int. Rev. Neurobiol."},{"issue":"6","key":"10.1016\/j.ejphar.2015.02.025_bib38","first-page":"a012880","article-title":"Rational development of addiction pharmacotherapies: successes, failures, and prospects","volume":"2","author":"Pierce","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ejphar.2015.02.025_bib39","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00213-013-3252-0","article-title":"Effects of dopamine receptor antagonists on the acquisition of ethanol-induced conditioned place preference in mice","volume":"231","author":"Pina","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2015.02.025_bib40","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s00213-002-1347-0","article-title":"Suppression of cocaine- and food-maintained behavior by the D2-like receptor partial agonist terguride in squirrel monkeys","volume":"166","author":"Platt","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2015.02.025_bib41","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0022-3565(24)37716-X","article-title":"Characterization of the effects of the partial dopamine agonist terguride on cocaine self-administration in the rat","volume":"286","author":"Pulvirenti","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2015.02.025_bib42","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/0165-6147(94)90158-9","article-title":"Dopamine receptor agonists, partial agonists and psychostimulant addiction","volume":"15","author":"Pulvirenti","year":"1994","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2015.02.025_bib43","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1098\/rstb.2008.0093","article-title":"Review. The incentive sensitization theory of addiction: some current issues","volume":"363","author":"Robinson","year":"2008","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.ejphar.2015.02.025_bib46","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00213-006-0520-2","article-title":"Effects of aripiprazole on operant responding for a natural reward after psychostimulant withdrawal in rats","volume":"191","author":"Schwabe","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2015.02.025_bib47","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2015.02.025_bib48","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1254\/jphs.11201FP","article-title":"Effect of aripiprazole on anxiety associated with ethanol physical dependence and on ethanol-induced place preference","volume":"118","author":"Shibasaki","year":"2012","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2015.02.025_bib50","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00213-008-1069-z","article-title":"Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice","volume":"199","author":"Sorensen","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2015.02.025_bib51","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00213-006-0621-y","article-title":"Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies","volume":"190","author":"Stark","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2015.02.025_bib52","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.biopsych.2012.06.018","article-title":"The monoamine stabiliser (-)-OSU6162 attenuates voluntary ethanol intake and ethanol-induced dopamine output in nucleus accumbens","volume":"72","author":"Steensland","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2015.02.025_bib53","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1098\/rstb.2008.0084","article-title":"Review. Psychological and neural mechanisms of relapse","volume":"363","author":"Stewart","year":"2008","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.ejphar.2015.02.025_bib54","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.tips.2008.03.009","article-title":"Antipsychotic drug action: antagonism, inverse agonism or partial agonism","volume":"29","author":"Strange","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2015.02.025_bib55","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/sj.bjp.0707672","article-title":"Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors","volume":"153","author":"Strange","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.02.025_bib56","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s007020200033","article-title":"Partial dopamine agonists in the treatment of psychosis","volume":"109","author":"Tamminga","year":"2002","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.ejphar.2015.02.025_bib57","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00213-008-1245-1","article-title":"Effects of acute and chronic aripiprazole treatment on choice between cocaine self-administration and food under a concurrent schedule of reinforcement in rats","volume":"201","author":"Thomsen","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2015.02.025_bib58","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjp.2008.30","article-title":"Neuropharmacology of alcohol addiction","volume":"154","author":"Vengeliene","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2015.02.025_bib59","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/bcpt.12036","article-title":"Effects of aripiprazole, an atypical antipsychotic, on the motor alterations induced by acute ethanol administration in mice","volume":"112","author":"Viana","year":"2013","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2015.02.025_bib60","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1038\/sj.npp.1301353","article-title":"Effect of aripiprazole, a partial dopamine D2 receptor agonist, on increased rate of methamphetamine self-administration in rats with prolonged session duration","volume":"32","author":"Wee","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2015.02.025_bib61","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nrn1406","article-title":"Dopamine, learning and motivation","volume":"5","author":"Wise","year":"2004","journal-title":"Nat. Rev. Neurosci."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299915001326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299915001326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:12:21Z","timestamp":1747699941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299915001326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":56,"alternative-id":["S0014299915001326"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2015.02.025","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dopamine receptor partial agonists and addiction","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2015.02.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}